U.S. Pot Legalization Bill Gets a Frosty Reception
(Bloomberg) -- The U.S. cannabis industry had eagerly awaited a federal legalization bill that executives, investors and interest groups had hoped would be a panacea for the partisan divide over a hotly contested issue.
What they saw last week from Senate Majority Leader Chuck Schumer left many underwhelmed.
Cannabis stocks flagged after the bill was unveiled, and critics piled on from all directions. It’s not a surprise that the legislation wouldn’t please everyone, given the controversies around cannabis. Even the bill’s own authors acknowledge shortcomings, saying in a summary of the proposal that there’s still no standard to measure drugged driving, or research on how marijuana affects fetal health, and that limits their ability to be as comprehensive as they’d like. The plan is to fund more research on those and other topics, but that could take years.
Other omissions include basic measures to protect public health, according to Smart Approaches to Marijuana, a group that prefers decriminalization of marijuana possession rather than full legalization.
In a letter last week to Schumer and the bill’s other backers, the group’s scientific advisory board -- mostly academics or doctors specializing in health and addiction -- recommended that the bill put a cap on marijuana potency, a ban or severe limitations on advertising, and a ban on flavored products or goods that would be attractive to children. It should also propose ways to stop the tobacco and alcohol industry from monopolizing the market, Smart Approaches to Marijuana said.
“States that commercialized the drug are seeing rising rates of youth use, hospitalizations, poison center calls and other negative outcomes related to the drug,” the group said in the letter.
The United Food and Commercial Workers, the union that represents the most workers in the cannabis industry at about 10,000, also took issue with the legislation. It said more should be done to support good-paying cannabis jobs, and to stop the industry from moving high-wage union jobs from one state to low wage agricultural jobs in another. The union also seeks to increase research funding to support worker safety and apprenticeships.
Not everyone was pessimistic about the bill. It has many of the items sought by Democrats, which could make it harder to pass, but Cantor Fitzgerald analyst Pablo Zuanic said he sees areas where compromises could happen in the coming months to improve the bill’s prospects.
For instance, lawmakers could offer incentives to states for expungement or re-sentencing of past marijuana crimes. Or they could set limits on funds that flow to so-called “opportunity programs” to help disadvantaged communities, thereby freeing up dollars for other federal and state programs.
Zuanic said just having a U.S. Senate majority leader proposing broad marijuana reform is a victory for the industry overall. Compared to high-priority political projects like infrastructure, voting rights and climate change, marijuana may “prove less divisive in the end,” he wrote in a July 15 research note.
The analyst urged investors to take advantage of the weakness in stock prices, saying his top U.S. stock picks are still the big multistate operators like Curaleaf Holdings Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp. and Cresco Labs Inc.. Canadian companies could also benefit as long as they have strong balance sheets, Zuanic said.
NUMBER OF THE WEEK
- $3 billion: The forecast for legal cannabis sales this year in the Midwest, which is expected to make up 15% of total legal cannabis sales in the U.S. by 2026, according to BDSA’s market outlook for 8 states that make up the region.
QUOTE OF THE WEEK
“I think the bill has a lot of questions -- more questions than answers. But it’s good to begin a dialogue,” said Green Thumb Industries Chief Executive Officer Ben Kovler in a phone interview about the new draft legalization bill.
WHAT YOU NEED TO KNOW
- Schumer’s bill to legalize marijuana has a long and uncertain path to passage. If it does make it through, it could open up banking and stock exchanges to cannabis companies.
- Getting the bill passed into law will be an uphill climb, analysts said, sending marijuana stocks down.
- Rahul Gupta, a primary care physician who’s currently the chief medical and health officer at the March of Dimes, has been nominated to be the new “drug czar,” or director of the Office of National Drug Control Policy.
- Curaleaf named Ranjan Kalia as chief financial officer to succeed Michael Carlotti, who is stepping down for medical reasons.
- Actor Sacha Baron Cohen sued a Massachusetts cannabis company, saying it misappropriated his likeness by using his “Borat” character on a billboard.
©2021 Bloomberg L.P.